CGMP Deviations; presence of N-nitroso-duloxetine impurity above recommended interim limit.
Classification
Class II
Status
Ongoing
Lot
a) NDC 70518-0937-04, Lot # J0786744-061724, Exp. 06/30/2025 b) NDC 70518-0937-03, Lot # B3002625-060524, Exp. 10/31/2025
Date
Disclaimer: This tool indexes published US FDA drug-enforcement recall records from all countries, limited to the latest five years. A company or product not appearing here is not proof that it is compliant, approved, safe, or free of FDA action.
RemedyRepack Inc. — Class II Recall | MedicineWatch US